Summary
Eli Lilly and Company's 2014 10-K filing reveals a challenging year primarily marked by significant revenue decline due to patent expirations for key products like Cymbalta and Evista. This led to a substantial decrease in net income and earnings per share compared to the previous year. Despite these headwinds, the company continued to invest heavily in research and development, focusing on core areas like diabetes and oncology. A major strategic move highlighted is the pending acquisition of Novartis Animal Health, expected to close in early 2015, which aims to significantly bolster Elanco's position in the animal health market. The company is navigating a complex operating environment characterized by intense competition from generic and biosimilar manufacturers, increasing pricing and reimbursement pressures from payers, and ongoing patent challenges. Lilly is actively managing its patent portfolio and investing in a robust late-stage pipeline to offset upcoming patent cliffs. The financial performance in 2014 was also impacted by various charges related to restructuring, asset impairments, and a one-time accelerated expense recognition for the U.S. Branded Prescription Drug Fee.
Financial Highlights
52 data points| Revenue | $19.62B |
| Cost of Revenue | $4.93B |
| Gross Profit | $14.68B |
| R&D Expenses | $4.73B |
| SG&A Expenses | $6.62B |
| Interest Expense | $148.80M |
| Net Income | $2.39B |
| EPS (Basic) | $2.23 |
| EPS (Diluted) | $2.23 |
| Shares Outstanding (Basic) | 1.07B |
| Shares Outstanding (Diluted) | 1.07B |
Key Highlights
- 1Significant revenue and net income decline in 2014 primarily due to patent expiries of Cymbalta and Evista, leading to increased generic competition.
- 2Heavy investment in R&D ($4.73 billion in 2014) continues, with a focus on diabetes, oncology, neuroscience, immunology, and pain, showcasing a robust pipeline with multiple late-stage candidates.
- 3Completion of the acquisition of Novartis Animal Health for approximately $5.4 billion is a major strategic initiative expected to strengthen the Elanco division.
- 4The company is actively engaged in patent litigation and administrative proceedings for key products like Alimta and Effient, highlighting the importance of intellectual property protection.
- 5Increased pricing and reimbursement pressures from managed care organizations and government entities globally are noted as significant ongoing challenges.
- 6Year-over-year revenue decreased by 15%, driven by a 29% drop in U.S. revenue, while international revenue saw a modest 3% increase.
- 7The company repurchased $800 million of its stock in 2014 as part of its ongoing share repurchase program.